

# Unlocking the science of longevity to develop transformative therapies

Corporate Presentation • August 2024

## Forward-looking statements

This presentation contains statements about BioVie’s future expectations, plans, strategies and prospects which constitute forward-looking statements. These forward-looking statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. BioVie has in some cases identified forward-looking statements by using words such as “anticipates,” “believes,” “hopes,” “estimates,” “looks,” “expects,” “plans,” “intends,” “goal,” “potential,” “may,” “suggest,” and similar expressions. Forward-looking statements are subject to risks, uncertainties and assumptions that could cause BioVie’s actual results and experience to differ materially from anticipated results and expectations expressed in these forward-looking statements. Among other factors that could cause actual results to differ materially from those expressed in forward-looking statements are: the Company’s ability to raise the substantial capital needed to fund its operations and research and development; risks associated with clinical development and the Company’s ability to successfully complete pre-clinical and clinical testing and be granted regulatory approval for its products to be sold and marketed in the United States or elsewhere; the Company’s reliance on third parties to conduct its clinical trials and manufacture its product candidates; the Company’s ability to establish and/or maintain intellectual property rights covering its product candidates; competition; and other risks described in greater detail in the Company’s filings with the Securities and Exchange Commission (the “SEC”). In addition to the risks described above and in BioVie’s filings with the SEC, other unknown or unpredictable factors also could affect BioVie’s results. No forward-looking statements can be guaranteed and actual results may differ materially from such statements. You should not place undue reliance on any forward-looking statements. BioVie undertakes no obligation to release publicly the results of any revisions to any such forward-looking statements that may be made to reflect events or circumstances after the date that these slides are posted to BioVie’s website or to reflect the occurrence of unanticipated events, except as required by applicable law or regulation.

# Overview

Our lead asset bezisterim (formerly NE3107) modulates the production of TNF $\alpha$ . In clinical trials, many patients treated with bezisterim experienced:


- Reduced inflammation and the associated insulin resistance
- Improved motor control and “morning on” symptoms in Parkinson’s disease (PD)
- Improved cognition and function, lowered amyloid  $\beta$  and p-tau levels, and improved brain imaging scans in Alzheimer’s Disease (AD)
- Lowered DNA methylation levels

BIV201 reduces fluid build up and has the potential to become the first therapeutic for ascites, a condition with 50% mortality rate within 12 months


## Our priorities:

- Launch Parkinson’s Phase 2b trial Fall 2024
- Launch next Alzheimer’s Phase 3 trial in mid-2025 using new once-daily formulation of bezisterim
- Continue partnering conversations for bezisterim (geographic rights)
- Launch ascites Phase 3 when partner identified

# Far-reaching impact of TNF $\alpha$ -mediated chronic low-grade inflammation



# Bezisterim's mechanism of action




First-in-class molecule with desirable characteristics


Small molecule; orally bioavailable

Crosses blood-brain barrier, thus CNS and peripheral applications

No safety issues identified to date in pre-clinical and clinical trials (up to Phase 2)




Bezisterim Reduces ERK Activation



Lu 2010 Am J Physiol Endocrinol Metab 298 E1036

Bezisterim Reduces NFκB Activation




Wang 2010 J Pharmacol Exp Ther 333 70

The background of the slide is a vibrant blue gradient. On the left side, there are several overlapping, wavy lines in shades of blue and purple, creating a sense of motion and depth. On the right side, there is a large, stylized graphic of a human eye. The eye is composed of various geometric shapes, including circles, lines, and dots, which are rendered in a light blue and white color scheme, giving it a futuristic, digital appearance. The overall aesthetic is clean, modern, and scientific.

# Bezisterim in Parkinson's Disease


# Low Dopamine *and* inflammation are required to develop Parkinson symptoms in patients

Intranasal Insulin treatment reduced inflammation and improved motor activity




# Bezisterim has similar promotoric activity to L-dopa in rodent\* and marmoset\* models

## MPTP Mouse



## MPTP Marmoset treated at Week 8



L-dopa and bezisterim combination is better than either drug alone

\*p<0.001 compared to other treatment arm in time period

\*\* L-Dopa at week 11 not statistically different from bezisterim at weeks 8 and 9


bezisterim's promotoric effects observed within 4 days of treatment



# Bezisterim decreases L-Dopa-induced dyskinesia (LID) in marmosets\*

Funded by  
  
THE MICHAEL J. FOX FOUNDATION  
FOR PARKINSON'S RESEARCH



## Distribution of AIMS Scores




# Bezisterim preserved ~2X TH+ (dopaminergic) neurons in MPTP marmosets\*

Funded by  
  
THE MICHAEL J. FOX FOUNDATION  
FOR PARKINSON'S RESEARCH


Control moneys (M09100 and M11008)



Bezisterim



Amantadine (M10084)



# Parkinson's Disease Clinical Development Program

## NM201 Phase 2


- Satisfying FDA requirement for drug-drug interaction study with L-dopa
- Detect efficacy signal for bezisterim's pro-motoric activity

40 patients with defined L-dopa "off state", 1:1 active: placebo, 20 mg BID for 28 days

- **Safety assessments:** Standard measures of patient health, L-dopa PK and DDI
- **Efficacy assessments:** MDS-UPDRS\* parts 1-3, Hauser ON/OFF Diary, Non-Motor Symptom Scale

# Bezisterim-treatment patients experienced fewer motor symptoms before morning drug administration

Day 28 Improvement in Motor Control vs. Day 1




	Bezisterim	Placebo
“On” at t=0	6	0
Total patients	20	19
P-value*	0.02	




\* Fisher’s exact test

# Larger proportion of patients treated with bezisterim had >30% improvements in motor control

Percentage of patients experiencing >30% improvement at Day 28 vs. Day 0




# Desirable pharmacokinetics – no observed DDI



The background of the slide is a vibrant blue gradient. On the left side, there are several overlapping, wavy lines in shades of blue and purple, creating a sense of motion and depth. On the right side, there is a large, stylized graphic of a human eye. The eye is composed of various geometric shapes, including circles, lines, and dots, which are rendered in a light blue and white color scheme, giving it a futuristic, digital appearance. The overall aesthetic is clean, modern, and scientific.

# Bezisterim in Alzheimer's Disease

# Bezisterim modulates inflammation at the central hub, thereby potentially reducing downstream cascade





# NM101 Phase 3 trial in Mild to Moderate Alzheimer's

A Phase 3, Double-blind, Randomized, Placebo-controlled, Parallel Group, Multicenter Study of bezisterim. Enrolled 439 Patients who have Mild to Moderate AD

- Pivotal study for Alzheimer's disease. Two weeks each of 5 mg and 10 mg BID dose titration followed by 26 weeks of 20 mg twice daily vs. placebo; 1:1 randomization; 80% power
- Diagnosed with probable AD and without evidence of a vascular contribution. Mild to moderate disease. CDR 1-2. MMSE 14-24.
- 60-85 years old, males and females
- Randomization stratified by MMSE and Homeostatic Model Assessment 2 Insulin Resistance (HOMA2)
- **Co-primary endpoints**
  - Mean change from Baseline to Week 30 in Dementia Rating-Sum of Boxes (CDR-SB) comparing the bezisterim group to the placebo group
  - Mean change from Baseline to Week 30 in the twelve-question form of the Alzheimer's Disease Assessment Scale-Cognitive (ADAS-Cog 12) comparing the bezisterim group to the placebo group
- **Secondary endpoints**
  - ADCS-ADL (functional), Alzheimer's Disease Cooperative Study-Clinical Global Impression of Change (ADCS-CGIC), ADCOMS (4 Alzheimer's Disease Assessment Scale-cognitive subscale items, 2 Mini-Mental State Examination items, and all 6 Clinical Dementia Rating-Sum of Boxes items), NPI-12 (care-giver rating of behavioral changes), MMSE, CDR
  - Glycemic control: HOMA2, Mean Amplitude of Glycemic Excursion (MAGE) using continuous glucose monitoring, fructosamine levels, post-prandial glucose and fasting blood glucose vs time.
  - MRI total hippocampus volume change, baseline to end of treatment in a subset of active and placebo subjects
  - Target engagement assessed in a small subset of active and placebo subjects using PET to quantify cortical glucose utilization

# Trial Summary

- Bezisterim appears to be biologically active
- Cognitive, functional, biomarker efficacy signal suggest that bezisterim:
  - Has a treatment advantage equal to or greater than results reported from clinical trials from approved monoclonal antibody treatments;
  - Associated with a benign safety profile
- Unanticipated exclusion of 258 patients from 15 sites due to deviations led to study being underpowered

# Week 30 Suggest bezisterim Advantage vs. Placebo is Comparable to or Better than Results Reported from Clinical Trials by Approved Medications




## Change from baseline

	Placebo Decline	Bezisterim	Bezisterim vs. Placebo	Comparator (18 mos)
<b>CDR-SB</b> (lower is improvement)	+1.39 (p=0.0125; n=26)	+0.44 (p=0.4522; n=24)	-0.95 (68%) (p=0.2278)	-0.45 (27%) <sup>1</sup> -0.39 (22%) <sup>2</sup>
<b>ADAS-Cog12</b> (lower is improvement)	+3.64 (p=0.0545; n=23)	+2.70 (p=0.1618; n=24)	-0.94 (26%) (p=0.7212)	-1.44 (25%) <sup>1</sup> -1.40 (27%) <sup>2</sup>
<b>MMSE</b> (higher is improvement)	-2.54 (p=0.0007; n=26)	-1.52 (p=0.0547; n=24)	+1.02 (40%) (p=0.3181)	+0.6 (18%) <sup>2</sup>
<b>ADCS-ADL</b> (higher is improvement)	-6.54 (p<0.0001; n=27)	-3.46 (p=0.0435; n=24)	+3.08 (47%) (p=0.1620)	+2.0 (36%) <sup>1</sup>
<b>ADCS-CGIC</b> (lower is improvement)	+0.31 (p=0.2733; n=26)	-0.12 (p=0.6951; n=24)	-0.43 (139%) (p=0.2866)	
<b>ADCOMS</b> (lower is improvement)	+0.11 (p=0.0358; n=22)	+0.09 (p=0.1094; n=24)	-0.03 (27%) (p=0.7063)	-0.05 (23%) <sup>1</sup>





<sup>1</sup> Lecanamab after 18 months; van Dyck et al. *N Engl J Med* 2023;388:9-2

<sup>2</sup> Aducunumab after 18 months; Haerberlein et al. *J Prev Alz Dis* 2022;2(9):197-210

# Bezisterim-treated Patients' Changes in CDR-SB Appears Correlated with Key Biomarkers



# Bezisterim Appears to Decrease the Neuroinflammatory Processes that Link Nf-L and GFAP to Cognitive Decline



# Safety Profile

	NE3107	Placebo	Total
COVID-19	9.5%	17.6%	13.2%
Urinary tract infection	7.1%	8.8%	7.9%
Blood thyroid stimulating hormone increased	7.1%	2.9%	5.3%
Fall	2.4%	8.8%	5.3%
Headache	9.5%	0.0%	5.3%
Diarrhoea	4.8%	2.9%	3.9%
Dizziness	2.4%	5.9%	3.9%
Hypertension	2.4%	5.9%	3.9%
Nausea	4.8%	2.9%	3.9%
Pneumonia	4.8%	2.9%	3.9%
Vomiting	2.4%	5.9%	3.9%
Blood testosterone decreased	0.0%	5.9%	2.6%
Gastroenteritis viral	0.0%	5.9%	2.6%
Nasopharyngitis	4.8%	0.0%	2.6%
Rash	0.0%	5.9%	2.6%
Thyroxine decreased	2.4%	2.9%	2.6%
Tri-iodothyronine decreased	2.4%	2.9%	2.6%
Abdominal pain	0.0%	2.9%	1.3%
Abdominal pain upper	0.0%	2.9%	1.3%
Accelerated idioventricular rhythm	2.4%	0.0%	1.3%
Agitation	0.0%	2.9%	1.3%
Aortic valve replacement	2.4%	0.0%	1.3%

	NE3107	Placebo	Total
Atrioventricular block first degree	2.4%	0.0%	1.3%
Bile duct stone	0.0%	2.9%	1.3%
Blood lactate dehydrogenase abnormal	0.0%	2.9%	1.3%
Blood prolactin decreased	2.4%	0.0%	1.3%
Blood prolactin increased	2.4%	0.0%	1.3%
Blood sodium abnormal	0.0%	2.9%	1.3%
Blood sodium increased	0.0%	2.9%	1.3%
Blood thyroid stimulating hormone decreased	0.0%	2.9%	1.3%
Bronchitis	0.0%	2.9%	1.3%
Calculus bladder	2.4%	0.0%	1.3%
Cholelithiasis	2.4%	0.0%	1.3%
Cough	0.0%	2.9%	1.3%
Delirium	0.0%	2.9%	1.3%
Dementia Alzheimer's type	2.4%	0.0%	1.3%
Dermatitis	2.4%	0.0%	1.3%
Dysphagia	2.4%	0.0%	1.3%
Dysuria	0.0%	2.9%	1.3%
Electrocardiogram abnormal	2.4%	0.0%	1.3%
Eosinophil count increased	2.4%	0.0%	1.3%
Eustachian tube dysfunction	2.4%	0.0%	1.3%
Hordeolum	0.0%	2.9%	1.3%
Hyperkalaemia	2.4%	0.0%	1.3%

	NE3107	Placebo	Total
Hypothyroidism	2.4%	0.0%	1.3%
Hypoxia	0.0%	2.9%	1.3%
Incontinence	0.0%	2.9%	1.3%
Increased appetite	2.4%	0.0%	1.3%
Influenza	0.0%	2.9%	1.3%
Insomnia	2.4%	0.0%	1.3%
International normalised ratio increased	0.0%	2.9%	1.3%
Lethargy	2.4%	0.0%	1.3%
Lipase increased	0.0%	2.9%	1.3%
Muscle spasms	2.4%	0.0%	1.3%
Nephrolithiasis	0.0%	2.9%	1.3%
Nightmare	0.0%	2.9%	1.3%
Obsessive-compulsive disorder	2.4%	0.0%	1.3%
Oesophageal food impaction	0.0%	2.9%	1.3%
Optic ischaemic neuropathy	2.4%	0.0%	1.3%
Orthostatic hypotension	2.4%	0.0%	1.3%
Papilloedema	2.4%	0.0%	1.3%
Paranasal sinus discomfort	0.0%	2.9%	1.3%
Patient elopement	0.0%	2.9%	1.3%
Pelvic fracture	0.0%	2.9%	1.3%
Pharyngitis streptococcal	2.4%	0.0%	1.3%


The Biovie logo is located in the top right corner of the slide. It consists of the word "biovie" in a white, lowercase, sans-serif font, with a thin white horizontal line underneath the letters "io". The logo is set against a solid red rectangular background.

biovie

The background of the slide is a vibrant blue gradient. On the left side, there are several overlapping, wavy lines in shades of blue and purple, creating a sense of motion and depth. On the right side, there is a large, stylized graphic of a human eye. The eye is composed of various geometric shapes, including circles, lines, and dots, all in a light blue or white color, giving it a high-tech, digital appearance. The overall aesthetic is clean, modern, and scientific.

Bezisterim  
in Longevity

Clean DVD leads to clear picture and sound



Scratches & smudges lead to skips and blurs



## Impact of wear & tear on a laser's ability to decode DVDs

Quality of picture is dependent on the laser's ability to clearly decode the disk ...

The same thing happens in our body



# DNA methylation


DNA methylation happens when methyl groups are added to our DNA

- DNA methyltransferases add methyl groups to DNA
- Functionally the equivalent of scratches and smudges on a DVD surface
- The methyl groups interfere with RNA polymerase's ability to decode DNA

DNA methylation may happen where a cytosine is positioned next to guanine and is separated by a phosphate group (CpG)

- 28 million CpGs in genome

Hypermethylation of DNA is associated with many disease conditions




# Observations about DNA methylation

- DNA methylation increases as we age
- DNA methylation can be affected by behavioral (diet, exercise) and environmental factors
- DNA hypermethylation is associated with a large number of disease conditions, including various forms of cancers, age-related cognitive impairment and dementia, Parkinson's disease, cardiovascular disease, COPD and respiratory disease, chronic kidney disease, inflammatory bowel disease, sepsis, and many others\*
- Inflammation has been shown to be a driver of hypermethylation of DNA\*\*
- Extent of DNA methylation can be measured by various “clocks”

\* Wang Z Nucleic Acids Research, 2020, Vol. 48, No. 5; Sugden K Neurology 2022;99:e1402-e1413; Tang X DOI: 10.1002/mds.29157; Tabaeia S Artificial Cells, Nanomedicine, and Biotechnology, 47:1, 2031-2041; Qiu W Am J Respir Crit Care Med Vol 185, Iss. 4, pp 373–381, Feb 15, 2012; Rysz C Int. J. Mol. Sci. 2022, 23(13), 7108; Kraicy J Mucosal Immunology volume 9, pages 647–658 (2016); Rump K Sci Rep 9, 18511 (2019)


\*\* Stenvinkel P doi: 10.1111/j.1365-2796.2007.01777.x

# DNA methylation “clocks” measure extent of aging and biological function



# Bezisterim-treated subjects showed a lower biological age than placebo subjects

**Age Deceleration**<sup>1</sup> is used by longevity researchers<sup>2</sup> to measure the difference between a person's biological age and the actual chronological age.



<sup>1</sup> Biological age as measured by the various “clocks” – Chronological Age

<sup>2</sup> Yusupov et al. *Neuropsychopharmacology* vol 48, 1409–1417 (2023)

The Biovie logo is located in the top right corner of the slide. It consists of the word "biovie" in a white, lowercase, sans-serif font, with a thin white horizontal line underneath the letters "io". The logo is set against a solid red rectangular background.

biovie

The title text "BIV201 in Ascites" is positioned in the bottom left corner of the slide. It is written in a white, bold, sans-serif font. The background behind the text features a blue gradient with abstract, wavy lines and faint, light-colored circuitry patterns.

BIV201  
in Ascites


# BIV201 Disease Target: Refractory Ascites

Refractory ascites patients typically undergo **paracentesis** to remove ascites fluid every week to 10 days

## Paracentesis:

- Withdrawal of 5–10L of ascites fluid (on average) from abdomen using a large bore needle
- Provides a few days of symptomatic relief
- The kidneys are “burning out” by retaining massive quantities of salt and water
- Patients suffer frequent life-threatening complications
- No remaining options except for TIPS<sup>1</sup> surgery or liver transplant
- Estimated \$1.6 billion addressable US market with 20,000<sup>2</sup> targeted patients

No drugs ever approved by FDA to treat ascites



Our first disease target is ascites, the accumulation of 5+ liters of fluid in the abdomen.

# Prefilled Syringe with Patent-pending Liquid Formulation

- BIV201\*** Our liquid formulation of terlipressin. We will seek patent protection in the US, Europe, China and Japan
- Accurate dosing** Eliminates mixing minute quantities of powder terlipressin that could result in medication errors or sterility loss
- Enhanced convenience** Simply inject fluid into the saline bag and attach to pump

BIV201 Prefilled Syringe  
Stable for 18+months at room temp.


Needle or Connector

50 mL bag of saline for insertion into pump

Portable pump  
Carried in small satchel



# BIV201 Phase 2b trial




Originally targeted 30 patients randomized 2:1

Paused enrollment based on encouraging data from the first 15 patients informing next steps

- 10 randomized to BIV201; 5 randomized to standard of care
- 5 completed 2 X 28-day cycles
- 5 discontinued treatment during or at end of Cycle 1



# Change in ascites volume 28d pre- vs post-treatment



53% reduction in ascites volume among patient completing BIV201 treatment

15% reduction among patients who started but did not complete treatment

3.1% increase for SOC patients

$p < 0.001$

# Next Steps: Phase 3 trial in participants with decompensated liver cirrhosis and ascites who have experienced a recent acute kidney injury

A Phase 3 randomized, open-label study evaluating the safety and efficacy of BIV201 continuous infusion compared to standard of care (SOC) alone to reduce further decompensation in participants with decompensated liver cirrhosis and ascites who have experienced a recent acute kidney injury (AKI).

- Male and female  $\geq 18$  years old diagnosed with cirrhosis and ascites
- Recent (within 2 weeks) recovery from an AKI experienced in outpatient or inpatient setting
- Required at least 2 paracenteses in previous 3 months.
- Randomized (1:1) to 3 months treatment with BIV201 (continuous intravenous infusion of terlipressin acetate) or SOC with 3 months follow-up for adverse events and outcomes and 6 months additional follow-up for major events from medical records. About 150 randomized participants to reach 80% power. 15-20 clinical sites (global)
- **Primary endpoint**
  - Incidence of any new or repeated occurrence of Grade 3 ascites, SBP, HE, AKI (including HRS-AKI), portal-hypertension-related GI bleeding at 3 months
- **Secondary endpoints**
  - Time to any primary outcome event including death or transplant
  - Incidence of Major Adverse Kidney Events at 3 and 6 months
  - Change in total number of therapeutic paracenteses
  - Days of hospitalization
  - Ascites-related symptoms (novel BioVie PRO under development)
  - Health related quality of life

# Commercial potential in US market alone\*

## Alzheimer's

**\$30B**

Annual sales for every  
1 million people treated

---

15% market penetration

---

\$30K/year much lower all-in cost vs.  
competition

---

## Parkinson's

**\$3B**

Annual sales for every  
100,000 people treated

---

10% market penetration

---

\$30K/year

---

## Ascites

**\$1.6B**

US peak sales

---

45% market penetration

---

\$45K/year

---

2026 launch

---

2032 peak sales

---

# Leadership Team

Deep expertise provides a strong foundation for success



**Cuong Do, President & Chief Executive Officer**

30+ years in biopharma & technology  
President, Samsung Global Strategy Group  
Chief Strategy Officer for Merck, Senior partner at McKinsey & Company



**Chris Reading, PhD, Neurodegenerative Disease Program**

40+ years in biopharma  
Chief Scientific Officer, Hollis-Eden Pharmaceuticals  
VP of Product and Process Dev. for Systemix  
U Texas Dept. of Tumor Biology



**David Morse, Chief Regulatory Officer**

35 years experience Regulatory Affairs and multi-region product development strategy  
Former VP with two top-5 international CRO's  
Former Associate Director CDER, FDA



**J. Wendy Kim, Chief Financial Officer**

35 years in finance/ accounting  
As CFO managed corporate finance and operations groups  
Closed M&A transactions and secured financings  
Combined 22 years at KPMG and BDO LLP



**Joseph Palumbo, MD, EVP, R&D and Chief Medical Officer**

30+ years treating patients; 25+ years in biopharma  
CMO, Zynerva  
Global Head of Medical Science & Translational Research, Global Head & Psychiatry Franchise Medical Leader, J&J



**Penelope Markham, Liver Cirrhosis Program**

25 years in biopharma drug development  
Lead Scientist Terlipressin (LATPharma/ BioVie 11 years)  
Head Research Biology Protez Pharma  
Co-founder/Director of Research Influx Inc.



**Clarence Ahlem, Operations**

35+ years in biopharma  
Vice President, Product Development Harbor Therapeutics  
Director, Product Development, Hollis-Eden Pharmaceuticals  
US San Diego

## Capitalization Table

As of March 31, 2024 ( Effected for reverse split 1:10)		
Common shares outstanding		6,116,552
Warrants (WAEP \$11.40)		1,932,029
Options ( WAEP \$54.11)		403,276
Restricted Stock units		49,424
Fully dilluted shares outstanding		8,501,281
Market Cap (June 28, 2024 close price \$4.0/share)	\$	24,466,208

# Recap

Our lead asset Bezisterim modulates the production of TNF $\alpha$ . In clinical trials, many patients treated with Bezisterim experienced:

- Reduced inflammation and the associated insulin resistance
- Improved cognition, lowered p-tau levels, and improved brain imaging scans in Alzheimer's Disease (AD)
- Improved motor control and “morning on” symptoms in Parkinson's disease (PD)
- Lowered DNA methylation levels

BIV201 reduces fluid build up and has the potential to become the first therapeutic for ascites, a condition with 50% mortality rate within 12 months

biovie

**Thank You**